Randomized, placebo‐controlled, phase 3 study of perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomib-Reference-Cited by-同舟云学术

Randomized, placebo‐controlled, phase 3 study of perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomib

Published:2020-04-06 Issue:1 Volume:1 Page:94-102
ISSN:2688-6146
Container-title:eJHaem
language:en
Short-container-title:eJHaem

Author:

Richardson Paul G.¹^ORCID,Nagler Arnon²,Ben‐Yehuda Dina³,Badros Ashraf⁴,Hari Parameswaran N.⁵,Hajek Roman⁶^ORCID,Spicka Ivan⁷,Kaya Hakan⁸,LeBlanc Richard⁹,Yoon Sung‐Soo¹⁰,Kim Kihyun¹¹,Martinez‐Lopez Joaquin¹²^ORCID,Mittelman Moshe¹³,Shpilberg Ofer¹⁴,Blake Paul¹⁵,Hideshima Teru¹,Colson Kathleen¹,Laubach Jacob P.¹^ORCID,Ghobrial Irene M.¹,Leiba Merav¹⁶,Gatt Moshe E.³^ORCID,Sportelli Peter¹⁷,Chen Michael¹⁸,Anderson Kenneth C.¹

Affiliation:

1. Jerome Lipper Center for Multiple Myeloma Research Dana‐Farber Cancer Institute Boston Massachusetts USA

2. Chaim Sheba Medical Center Tel Hashomer Israel

3. Hadassah University Hospital Jerusalem Israel

4. Greenebaum Comprehensive Cancer Center University of Maryland Baltimore Maryland USA

5. Department of Hematology/Oncology Medical College of Wisconsin Milwaukee Wisconsin USA

6. Department of Hematooncology University Hospital, Ostrava, and Faculty of Medicine University of Ostrava Ostrava Czech Republic

7. First Department of Medicine, Department of Hematology First Faculty of Medicine Charles University and General Hospital in Prague Prague Czech Republic

8. Cancer Care Northwest Spokane Washington USA

9. CIUSSS de l'est de l’île de Montréal University of Montreal Montreal Canada

10. Department of Internal Medicine Seoul National University College of Medicine Seoul South Korea

11. Sungkyunkwan University School of Medicine Samsung Medical Center Seoul South Korea

12. Hospital Universitario 12 de Octubre CNIO Complutense University Madrid Spain

13. Tel Aviv Sourasky Medical Center Tel Aviv Israel

14. Institute of Hematology Assuta Medical Centers Tel Aviv and Ariel University Ariel Israel

15. Aeterna Zentaris Frankfurt Germany

16. Assuta Ashdod University Hospital Faculty of Health Sciences Ben‐Gurion University of the Negev Beer‐Sheba Israel

17. Keryx Biopharmaceuticals Inc. New York New York USA

18. TCM Groups Inc. Berkeley Heights New Jersey USA

Funder

RJ Corman Multiple Myeloma Research Fund

Aeterna Zentaris GmbH

AOI Pharmaceuticals, Inc., a subsidiary of Keryx Biopharmaceuticals, Inc.

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jha2.4

Reference44 articles.

1. Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back

2. Navigating the treatment landscape in multiple myeloma: which combinations to use and when?

3. Recent advances in understanding multiple myeloma

4. Multiple myeloma

5. Society of Hematologic Oncology State of the Art Update and Next Questions: Multiple Myeloma

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Autophagy-related mechanisms for treatment of multiple myeloma;Cancer Drug Resistance;2023-12-25

2. Mitochondrial Functionality Is Regulated by Alkylphospholipids in Human Colon Cancer Cells;Biology;2023-11-22

3. Recent Advances in the Applications of Small Molecules in the Treatment of Multiple Myeloma;International Journal of Molecular Sciences;2023-01-31

4. Future Developments in the Treatment of AL Amyloidosis;Hemato;2022-02-07

5. Where We Stand With Precision Therapeutics in Myeloma: Prosperity, Promises, and Pipedreams;Frontiers in Oncology;2022-01-20